Jeon S,Lee WK.Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab[J].Retina,2014,34(8):1 606-1 611.
[2]
Pacella F,Francesca FA,Turchetti P,et al.Intravitreal injection of ozurdeximplant in patients with persistent diabetic macular edema,with six-month follow-up[J].Ophthalmol Eye Dis,2016,8:11-16.
[3]
Campochiaro PA,Brown DM,Pearson A,et al.Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3years in patients with diabetic macular edema[J].Ophthalmology,2012,119(10):2 125-2 132.
[4]
Wells JA,Glassman AR,Ayala AR,et al.Aflibercept,bevacizumab,or ranibizumab for diabetic macular edema:two-year results from a comparative effectiveness randomized clinical trial[J].Ophthalmology,2016,123(6):1 351-1 359.
[5]
Stewart MW,Jr FH,Schwartz SG,et al.Extended duration strategies for the pharmacologic treatment of diabetic retinopathy:Current status and future prospects[J].Expert Opinion on Drug Delivery,2016,13(9):1 277-1 287.
[6]
Elbendary AM,Shahin MM.Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema[J].Retina,2011,31(10):2 058-2 064.
[7]
Nakajima T,Roggia MF,Noda Y,et al.Effect of internal limiting membrane peeling during vitrectomy for diabetic macular edema:Systematic Review and Metaanalysis[J].Retina,2015,35(9):1 719-1 725.
[8]
Smithwick E,Stewart MW.Designed ankyrin repeat proteins:a look at their evolving use in medicine with a focus on the treatment of chorioretinal vascular disorders[J].Antiinflamm Antiallergy Agents in Medicinal Chemistry,2017,16(1):33-45.
[9]
Global report on diabetes[R].Geneva:World Health Organization,2016.
[10]
Ding J,Wong TY.Current epidemiology of diabetic retinopathy and diabetic macular edema[J].Current Diabetes Reports,2012,12(4):346-354.
[11]
中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)[J].中华眼科杂志,2014,50(11):851-865.Chinese Ocular Fundus Diseases Society,Chinese Ophthalmological Society,Chinese Medical Association.Guidelines for clinical diagnosis and treatment of diabetic retinopathy in China[J].Chin J Ophthalmol,2014,50(11):851-865.
[12]
Campochiaro PA,Channa R,Berger BB,et al.Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor:A PhaseⅠ/ⅡStudy[J].Am J Ophthalmol,2013,155(4):697-704,704.e1-e2.
[13]
Nguyen QD,Schachar RA,Nduaka CI,et al.Doseranging evaluation of intravitrealsiRNA PF-04523655for diabetic macular edema(the DEGAS study)[J].Invest Ophthalmol Vis Sci,2012,53(12):7 666-7 674.
[14]
Klein R,Klein BE,Moss SE,et al.The Wisconsin Epidemiologic Study of Diabetic Retinopathy.XV.The long-term incidence of macular edema[J].Ophthalmology,1995,102(1):7-16.
[15]
Keech AC,Mitchell P,Summanen PA.Effect of fenofibrate on the need for laser treatment for diabetic retinopathy(FIELD study):a randomised controlled trial[J].Lancet,2007,370(9 600):1 687-1 697.
Network DRC,Elman MJ,Aiello LP,et al.Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema[J].Ophthalmology,2010,117(6):1 064-1 077.
[18]
Zhang L,Si T,Fischer AJ,et al.Coaxial electrospray of ranibizumab-loaded microparticles for sustained release of Anti-VEGF therapies[J].Plos One,2015,10(8):e0135608.
[19]
Bagley RG,Kurtzberg L,Weber W,et al.sFLT01:a novel fusion protein with antiangiogenic activity.[J].Molecular Cancer Therapeutics,2011,10(3):404-415.
[20]
Shen J,Frye M,Lee BL,et al.Targeting VE-PTP activates TIE2and stabilizes the ocular vasculature[J].Journal of Clinical Investigation,2014,124(10):4 564-4 576.
[21]
Gupta A,Gupta V,Thapar S,et al.Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema[J].Am J Ophthalmol,2004,137(4):675-682.
[22]
Hoshikawa Y,Ohkoshi K.Association between pioglitazone and diabetic macular edema[J].Nippon Ganka Gakkai Zasshi,2013,117(4):357-363.
[23]
Network WCFRC,Fong DS,Strauber SF,et al.Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema[J].Archives of Ophthalmology,2007,125(4):469-480.
[24]
Chen G,Tzekov R,Li W,et al.Subthreshold micropulse diode laser versus conventional laser photocoagulation for diabetic macular edema:A meta-analysis of randomized controlled trials[J].Retina,2016,36(11):2 059-2 065.
[25]
Mansouri A,Sampat KM,Malik KJ,et al.Efficacy of subthresholdmicropulse laser in the treatment of diabetic macular edema is influenced by pre-treatment central foveal thickness[J].Eye,2014,28(12):1 418-1 424.
[26]
Singerman L.Combination therapy using the small interfering RNA bevasiranib[J].Retina,2009,29(6Suppl):S49-S50.
[27]
Cellini M,Balducci N,Strobbe E,et al.Subtenon injection of natural leukocyte interferonα-2ain diabetic macular edema:a case report[J].BMC Ophthalmology,2013,13(1):1-4.
[28]
Dugel PU,Blumenkranz MS,Haller JA,et al.A randomized,dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema[J].Ophthalmology,2012,119(1):124.
[29]
Campochiaro PA,Khanani A,Singer M,et al.Enhanced benefit in diabetic macular edema from akb-9778tie2activation combined with vascular endothelial growth factor suppression[J].Ophthalmology,2016,123(8):1 722-1 730.
[30]
Jm LDF,Jalkh AE,Trempe CL,et al.Diabetic macular edema,Risk factors and concomitants[J].Acta Ophthalmologica Scandinavica,1999,77(2):170-175.
[31]
Li W,Sinclair SH,Xu GT.Effects of intravitrealerythropoietin therapy for patients with chronic andprogressive diabetic macular edema[J].Ophthalmic Surg Lasers Imaging,2010,41(1):18-25.
